Trials / Completed
CompletedNCT01710371
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
Quantitative PET Imaging of Pancreatic Beta-Cell Mass in Healthy Overweight/Obese Subjects, Subjects With Prediabetes, and Type 2 Diabetes Patients With 18F-FP-DTBZ (18F-AV-133)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control subjects. These subjects will also be evaluated for beta-cell function as measured by the insulin and C-peptide response to a challenge with intravenous arginine under basal and glucose enhanced conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-AV-133 | 296 MBq (8 mCi) |
| DRUG | 10% Arginine Hydrochloride-R-Gene 10 |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2012-10-19
- Last updated
- 2015-11-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01710371. Inclusion in this directory is not an endorsement.